Patent for J&J's Remicade invalidated, cheaper version looms
Wednesday, August 17, 2016 - 18:21
in Mathematics & Economics
TRENTON, N.J. (AP) -- A cheaper version of Johnson & Johnson's top-selling drug, the pricey rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled that a key patent on the drug is invalid....